Mirum Pharmaceuticals, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Mirum Pharmaceuticals, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | $19.14M | Mar 9, 2022 |
| FY2021 | Dec 31, 2020 | $0 | Mar 9, 2022 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $521.31M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $336.89M | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $186.37M | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | $77.06M | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | $19.14M | Mar 15, 2024 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($23.36M) | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | ($87.94M) | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | ($163.42M) | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | ($135.67M) | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | ($83.99M) | Mar 15, 2024 |
| FY2021 | Dec 31, 2020 | ($103.27M) | Mar 9, 2022 |
| FY2020 | Dec 31, 2019 | ($52.55M) | Mar 9, 2021 |
| FY2019 | Dec 31, 2018 | ($17.35M) | Mar 12, 2020 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($22.14M) | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | ($87.61M) | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | ($109.15M) | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | ($131.22M) | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | ($173.41M) | Mar 15, 2024 |
| FY2021 | Dec 31, 2020 | ($104.30M) | Mar 9, 2022 |
| FY2020 | Dec 31, 2019 | ($54.74M) | Mar 9, 2021 |
| FY2019 | Dec 31, 2018 | ($17.41M) | Mar 12, 2020 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $257.03M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $202.22M | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $145.88M | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | $89.07M | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | $59.22M | Mar 15, 2024 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $55.83M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $10.33M | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | ($70.94M) | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | ($120.14M) | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | ($132.76M) | Mar 15, 2024 |
| FY2021 | Dec 31, 2020 | ($89.08M) | Mar 9, 2022 |
| FY2020 | Dec 31, 2019 | ($39.36M) | Mar 9, 2021 |
| FY2019 | Dec 31, 2018 | ($373.0K) | Mar 12, 2020 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $954.0K | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $993.0K | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $109.0K | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | $278.0K | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | $24.0K | Mar 15, 2024 |
| FY2021 | Dec 31, 2020 | $225.0K | Mar 9, 2022 |
| FY2020 | Dec 31, 2019 | $281.0K | Mar 9, 2021 |
| FY2019 | Dec 31, 2018 | $0 | Mar 12, 2020 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $842.81M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $670.75M | Feb 25, 2026 |
| FY2024 | Dec 31, 2023 | $646.62M | Feb 26, 2025 |
| FY2023 | Dec 31, 2022 | $352.91M | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | $294.65M | Mar 8, 2023 |
| FY2021 | Dec 31, 2020 | $240.86M | Mar 9, 2022 |
| FY2020 | Dec 31, 2019 | $146.71M | Mar 9, 2021 |
| FY2019 | Dec 31, 2018 | $51.98M | Mar 12, 2020 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $528.12M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $445.11M | Feb 25, 2026 |
| FY2024 | Dec 31, 2023 | $397.95M | Feb 26, 2025 |
| FY2023 | Dec 31, 2022 | $210.87M | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | $174.44M | Mar 8, 2023 |
| FY2021 | Dec 31, 2020 | $68.77M | Mar 9, 2022 |
| FY2020 | Dec 31, 2019 | $16.36M | Mar 9, 2021 |
| FY2019 | Dec 31, 2018 | $2.45M | Mar 12, 2020 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $314.69M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $225.64M | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $248.67M | Feb 25, 2026 |
| FY2025 | Dec 31, 2022 | $142.04M | Feb 25, 2026 |
| FY2024 | Dec 31, 2021 | $120.21M | Feb 26, 2025 |
| FY2023 | Dec 31, 2020 | $172.10M | Mar 15, 2024 |
| FY2021 | Dec 31, 2019 | $130.35M | Mar 9, 2022 |
| FY2020 | Dec 31, 2018 | ($17.31M) | Mar 9, 2021 |
| FY2019 | May 2, 2018 | $0 | Mar 12, 2020 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($667.54M) | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | ($644.18M) | Feb 25, 2026 |
| FY2024 | Dec 31, 2023 | ($556.24M) | Feb 26, 2025 |
| FY2023 | Dec 31, 2022 | ($392.82M) | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | ($257.16M) | Mar 8, 2023 |
| FY2021 | Dec 31, 2020 | ($173.17M) | Mar 9, 2022 |
| FY2020 | Dec 31, 2019 | ($69.90M) | Mar 9, 2021 |
| FY2019 | Dec 31, 2018 | ($17.35M) | Mar 12, 2020 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $296.68M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $222.50M | Feb 25, 2026 |
| FY2024 | Dec 31, 2023 | $286.33M | Feb 26, 2025 |
| FY2023 | Dec 31, 2022 | $28.00M | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | $31.34M | Mar 8, 2023 |
| FY2021 | Dec 31, 2020 | $142.09M | Mar 9, 2022 |
| FY2020 | Dec 31, 2019 | $11.97M | Mar 9, 2021 |
| FY2019 | Dec 31, 2018 | $51.96M | Mar 12, 2020 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | (4) | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | (4) | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | (2) | Mar 15, 2024 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | (4) | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | (4) | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | (2) | Mar 15, 2024 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 51.90M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | 48.34M | Feb 25, 2026 |
| FY2024 | Dec 31, 2023 | 46.72M | Feb 26, 2025 |
| FY2023 | Dec 31, 2022 | 36.96M | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | 30.58M | Mar 8, 2023 |
| FY2021 | Dec 31, 2020 | 29.78M | Mar 9, 2022 |
| FY2020 | Dec 31, 2019 | 22.60M | Mar 9, 2021 |
| FY2019 | Dec 31, 2018 | 636,719 | Mar 12, 2020 |